Filing Flows › Teladoc Health (TDOC) › Guidance & outlook
Teladoc Health (TDOC) guidance and outlook
Teladoc Health (TDOC) raised its guidance on Oct 28, 2026: Revenue $2.4B for FY2026; EBITDA $277M–$303M for FY2026; EPS −$0.95 to −$0.75 for FY2026; Free cash flow $135M–$165M for FY2026.
Guidance and outlook
Latest guidance
| Metric | Period | Range | Change |
|---|---|---|---|
| Revenue | FY2026 | $2.4B | raised |
| EBITDA | FY2026 | $277M–$303M | raised |
| EPS | FY2026 | −$0.95 to −$0.75 | raised |
| Free cash flow | FY2026 | $135M–$165M | reaffirmed |
| Revenue | FY2026 | +1.1% to +2.1% | reaffirmed |
| EBITDA margin | FY2026 | 16%–16.6% | raised |
| Revenue | Q4 2026 | $569M–$615M | new |
| EBITDA | Q4 2026 | $74.0M–$100M | new |
| EPS | Q4 2026 | −$0.23 to −$0.03 | new |
| Revenue | Q4 2026 | 0% to +3.8% | new |
| EBITDA margin | Q4 2026 | 14.5%–16.8% | new |
From the earnings release filed Oct 28, 2026 (8-K on EDGAR).
Teladoc Health's latest quarter
Teladoc Health, Q3 2026: revenue $605M (-3% year over year), operating margin -4.6%, net loss $26.9M, operating cash flow $106M. The chart follows the revenue to costs, profit and cash.
Questions
Did Teladoc Health raise or lower its guidance?
Teladoc Health (TDOC) raised its guidance on Oct 28, 2026: Revenue $2.4B for FY2026; EBITDA $277M–$303M for FY2026; EPS −$0.95 to −$0.75 for FY2026; Free cash flow $135M–$165M for FY2026.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.